Sponsored Links
| NICE Gives Green Light To MabThera(R) (Rituximab) For Wider Use In Patients With Most Common Chronic Leukaemia |
 |
 |
 |
| Medical News - Lymphoma and Leukemia | |||
|
The National Institute for Health and Clinical Excellence (NICE) extended its recommendation for the use of targeted antibody MabThera® (rituximab) to include people with relapsed and difficult-to-treat (refractory) chronic lymphocytic leukaemia (CLL) except where patients have received the full therapeutic dose of MabThera in the first line setting or are refractory to fludarabine... Read more: Lymphoma / Leukemia / Myeloma News From Medical News Today
|